Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Interferon alfacon-1
Drug ID BADD_D01168
Description Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional amino acid changes were made to facilitate the molecular construction, and a corresponding synthetic DNA sequence was constructed using chemical synthesis methodology. Interferon alfacon-1 differs from interferon alfa-2b at 20/166 amino acids (88% homology), and comparison with interferon-beta shows identity at over 30% of the amino acid positions. Interferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. Prior to final purification, Interferon alfacon-1 is allowed to oxidize to its native state, and its final purity is achieved by sequential passage over a series of chromatography columns. This protein has a molecular weight of 19,434 daltons.
Indications and Usage For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma
Marketing Status Not Available
ATC Code L03AB09; S01AD05
DrugBank ID DB00069
KEGG ID D02744
MeSH ID C050739
PubChem ID Not Available
TTD Drug ID D0GA0A
NDC Product Code Not Available
Synonyms interferon alfacon-1 | IFN-alpha Con 1 | consensus IFN-alpha | interferon-alpha Con(1) | rIFN-con-1 | recombinant consensus interferon alpha | CIFN (interferon) | Infergen | Inferax
Chemical Information
Molecular Formula Not Available
CAS Registry Number 118390-30-0
SMILES Not Available
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pain in extremity15.03.04.010--
Paraesthesia17.02.06.005--
Pharyngitis22.07.03.004; 07.05.07.004; 11.01.13.003--
Platelet count decreased13.01.04.001--
Pruritus23.03.12.001--
Pyoderma gangrenosum23.07.03.001; 16.32.03.005; 10.04.02.009--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rhabdomyolysis15.05.05.002--
Seizure17.12.03.001--
Sepsis11.01.11.003--
Sinusitis22.07.03.007; 11.01.13.005--
Speech disorder22.02.05.034; 19.19.02.002; 17.02.08.003--Not Available
Suicidal ideation19.12.01.003--
Thinking abnormal19.10.03.001; 17.02.05.023--Not Available
Thyroxine decreased13.10.06.007--Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Tremor17.01.06.002--
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Hypoacusis04.02.01.006--
Contusion24.07.06.001; 23.03.11.002; 15.03.01.008; 12.01.06.001--
Affect lability19.04.01.001--Not Available
Haemorrhage24.07.01.002--Not Available
Hepatic enzyme increased13.03.01.019--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Decreased appetite14.03.01.005; 08.01.09.028--
The 3th Page    First    Pre   3    Total 3 Pages